Skip to main content

Loading component...

Loading component...

Multi-drug resistant tuberculosis (MDR-TB) is one of the world's major public health challenges. The Eli Lilly Foundation’s MDR-TB Partnership enlisted Innosight to convene a group of multi-disciplinary thinkers for an ideation event aimed at new solutions.

CONFRONTING A GLOBAL HEALTH CRISIS

Eli-Lilly-body-2.jpg

The two-day event attracted a wide range of leaders—including public health and supply chain experts—from places as diverse as the World Health Organization (WHO), MIT, Partners in Health, and Wal-Mart. eli-lilly-body-2Convening at Innosight’s Business Design Lab, the MDR-TB Solutions Summit began by laying out the severity of the problem for those who held no expertise in global health. Since tuberculosis has been around for thousands of years and because vaccines are fairly cheap, there’s a perception in the developed world that the problem is well under control. But that’s not the case for “multi-drug resistant,” or MDR-TB, which arises when treatments are improperly applied. MDR-TB accounts for about 10% of total TB fatalities worldwide, or about 150,000 deaths per year, according to USAID. The highest concentrations of the disease occur in India, China, Russia, and many parts of Africa. “Due to incorrect treatment, MDR-TB is a man-made disease,” said Lucica Ditiu, executive secretary at WHO. “That is unacceptable.”

Eli Lilly: Structured Collaboration Leads to New Solutions to a Global Health Crisis video player ready

Innosight

Eli Lilly: Structured Collaboration Leads to New Solutions to a Global Health Crisis

maxresdefault_eli.jpg

Loading component...